Search results
Biogen Inc. (NASDAQ:BIIB) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Simply Wall St. via Yahoo Finance· 9 hours agoIt's been a good week for Biogen Inc. (NASDAQ:BIIB) shareholders, because the company has just...
Biogen earnings beat by $0.24, revenue fell short of estimates
Investing.com· 4 days agoBiogen earnings beat by $0.24, revenue fell short of estimates
Decoding Biogen Inc (BIIB): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 2 days agoBiogen Inc's robust product portfolio and pipeline offer a competitive edge in the neurology and immunology sectors. Despite a slight revenue dip, Biogen
Biogen Inc. (NASDAQ:BIIB) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 days agoBiogen Inc. (NASDAQ:BIIB) Q1 2024 Earnings Call Transcript April 24, 2024 Biogen Inc. misses on...
Biogen Surges After Two Notable Drugs Wallop Sales Forecasts
Investor's Business Daily· 3 days agoTwo of Biogen's (BIIB) newest drugs, Leqembi and Skyclarys, walloped first-quarter sales...
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Zacks via Yahoo Finance· 1 day agoEvery day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and...
Biogen (NASDAQ:BIIB) Sees Unusually-High Trading Volume on Earnings Beat
ETF DAILY NEWS· 1 day agoBiogen Inc. (NASDAQ:BIIB – Get Free Report) shares saw strong trading volume on Wednesday following a better than expected earnings announcement. Biogen ...
Biogen stock gains on Q1 earnings beat (NASDAQ:BIIB)
Seeking Alpha· 3 days agoBiogen (BIIB) reports improving uptake for its Alzheimer's therapy Leqembi with its Q1 2024 results as global sales for the drug reach $19M. Read more...
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
Zacks via Yahoo Finance· 3 days agoBiogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key...
Brokerages Set Biogen Inc. (NASDAQ:BIIB) Price Target at $295.58
ETF DAILY NEWS· 2 days agoShares of Biogen Inc. (NASDAQ:BIIB – Get Free Report) have earned a consensus rating of “Moderate Buy” from the twenty-seven research firms that are covering the company, ...